David J. Ellam
Director/Board Member at LyGenesis, Inc.
Profile
David J.
Ellam is currently a Director at LyGenesis, Inc. He was previously a Senior Finance Director at BioMarin Pharmaceutical, Inc. from 2010 to 2016, CFO, Secretary & Executive Director at Silence Therapeutics Plc from 2016 to 2019, Chief Financial Officer at Plethora Solutions Holdings Plc in 2009, and Group Financial Controller at Premier Veterinary Group Plc from 2001 to 2008.
Ellam obtained an undergraduate degree from the University of Birmingham.
David J. Ellam active positions
Companies | Position | Start |
---|---|---|
LyGenesis, Inc.
LyGenesis, Inc. BiotechnologyHealth Technology LyGenesis, Inc. operates as a biotechnology company. It develops an organ regeneration technology platform enabling a patient's lymph nodes to be used as bioreactors to regrow functioning ectopic organs. The company is headquartered in Pittsburgh, PA. | Director/Board Member | - |
Former positions of David J. Ellam
Companies | Position | End |
---|---|---|
SILENCE THERAPEUTICS PLC | Director of Finance/CFO | 09/01/2019 |
BIOMARIN PHARMACEUTICAL INC. | Corporate Officer/Principal | 01/01/2016 |
PLETHORA SOLUTIONS HOLDINGS PLC | Director of Finance/CFO | 19/02/2009 |
PREMIER VETERINARY GROUP PLC | Comptroller/Controller/Auditor | 01/01/2008 |
Training of David J. Ellam
University of Birmingham | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
SILENCE THERAPEUTICS PLC | Commercial Services |
BIOMARIN PHARMACEUTICAL INC. | Health Technology |
Private companies | 3 |
---|---|
Plethora Solutions Holdings Plc
Plethora Solutions Holdings Plc Pharmaceuticals: MajorHealth Technology Plethora Solutions Holdings Plc operates as a pharmaceutical company. It engages in the development and marketing of products for the treatment and management of urological disorders. The firm operates through the Plethora Development and The Urology Co. segments. The Plethora Development segment develops new pharmaceutical products. The Urology Co. segment sells and markets pharmaceutical and healthcare products. The company was founded by Michael Grant Wyllie and Neil Brent Stafford in December 2003 and is headquartered in Chalgrove, the United Kingdom. | Health Technology |
Premier Veterinary Group Plc
Premier Veterinary Group Plc Agricultural Commodities/MillingProcess Industries Premier Veterinary Group Plc provides veterinary health care services. It operates through the following segments: Premier Pet Care Plan (PPCP) United Kingdom, PPCP Europe, and PPCP USA. The firm also administers a small animal wellness plan, branded pet care plan both for its own surgeries and for third party surgeries. The company was founded on October 31, 2001 and is headquartered in Bristol, the United Kingdom. | Process Industries |
LyGenesis, Inc.
LyGenesis, Inc. BiotechnologyHealth Technology LyGenesis, Inc. operates as a biotechnology company. It develops an organ regeneration technology platform enabling a patient's lymph nodes to be used as bioreactors to regrow functioning ectopic organs. The company is headquartered in Pittsburgh, PA. | Health Technology |
- Stock Market
- Insiders
- David J. Ellam